Anaveon’s CHF 110 Million Series B Financing Round

VISCHER advised Anaveon on the deal.Anaveon AG, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor Forbion,…

This content is for Standard 1 Year members only.
Login Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

This content is for Standard 1 Year members only.
Login Join Now